385 related articles for article (PubMed ID: 33186655)
1. Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: A potential target for anti-CSC cancer therapy.
Praharaj PP; Panigrahi DP; Bhol CS; Patra S; Mishra SR; Mahapatra KK; Behera BP; Singh A; Patil S; Bhutia SK
Cancer Lett; 2021 Feb; 498():217-228. PubMed ID: 33186655
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of mitophagy and mitochondrial homeostasis in cancer stem cells: Novel mechanism for anti-cancer stem cell-targeted cancer therapy.
Praharaj PP; Patro BS; Bhutia SK
Br J Pharmacol; 2022 Nov; 179(22):5015-5035. PubMed ID: 33527371
[TBL] [Abstract][Full Text] [Related]
3. Role of Mitochondria in Cancer Stem Cell Resistance.
García-Heredia JM; Carnero A
Cells; 2020 Jul; 9(7):. PubMed ID: 32679735
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria in cancer stem cells: Achilles heel or hard armor.
Zheng XX; Chen JJ; Sun YB; Chen TQ; Wang J; Yu SC
Trends Cell Biol; 2023 Aug; 33(8):708-727. PubMed ID: 37137792
[TBL] [Abstract][Full Text] [Related]
5. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics.
Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Patra S; Behera BP; Mishra SR; Bhutia SK
Semin Cancer Biol; 2020 Nov; 66():45-58. PubMed ID: 31351198
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies.
Skoda J; Borankova K; Jansson PJ; Huang ML; Veselska R; Richardson DR
Pharmacol Res; 2019 Jan; 139():298-313. PubMed ID: 30453033
[TBL] [Abstract][Full Text] [Related]
7. A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.
Ozsvari B; Sotgia F; Lisanti MP
Aging (Albany NY); 2017 Oct; 9(10):2098-2116. PubMed ID: 29080556
[TBL] [Abstract][Full Text] [Related]
8. The mitochondrial fission factor FIS1 promotes stemness of human lung cancer stem cells via mitophagy.
Liu D; Sun Z; Ye T; Li J; Zeng B; Zhao Q; Wang J; Xing HR
FEBS Open Bio; 2021 Jul; 11(7):1997-2007. PubMed ID: 34051059
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito-stemness and ribo-stemness features.
Peiris-Pagès M; Ozsvári B; Sotgia F; Lisanti MP
Aging (Albany NY); 2019 Jul; 11(14):4801-4835. PubMed ID: 31311889
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.
De Luca A; Fiorillo M; Peiris-Pagès M; Ozsvari B; Smith DL; Sanchez-Alvarez R; Martinez-Outschoorn UE; Cappello AR; Pezzi V; Lisanti MP; Sotgia F
Oncotarget; 2015 Jun; 6(17):14777-95. PubMed ID: 26087310
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells.
Yan C; Luo L; Guo CY; Goto S; Urata Y; Shao JH; Li TS
Cancer Lett; 2017 Mar; 388():34-42. PubMed ID: 27913197
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.
Shen YA; Wang CY; Hsieh YT; Chen YJ; Wei YH
Cell Cycle; 2015; 14(1):86-98. PubMed ID: 25483072
[TBL] [Abstract][Full Text] [Related]
13. Metabostemness in cancer: Linking metaboloepigenetics and mitophagy in remodeling cancer stem cells.
Naik PP; Panigrahi S; Parida R; Praharaj PP; Bhol CS; Patil S; Manjunath N; Ghosh D; Patra SK; Bhutia SK
Stem Cell Rev Rep; 2022 Jan; 18(1):198-213. PubMed ID: 34355273
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling.
Lamb R; Bonuccelli G; Ozsvári B; Peiris-Pagès M; Fiorillo M; Smith DL; Bevilacqua G; Mazzanti CM; McDonnell LA; Naccarato AG; Chiu M; Wynne L; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2015 Oct; 6(31):30453-71. PubMed ID: 26421711
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dynamics in cancer stem cells.
Sessions DT; Kashatus DF
Cell Mol Life Sci; 2021 Apr; 78(8):3803-3816. PubMed ID: 33580834
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).
Fiorillo M; Tóth F; Sotgia F; Lisanti MP
Aging (Albany NY); 2019 Apr; 11(8):2202-2216. PubMed ID: 31002656
[TBL] [Abstract][Full Text] [Related]
17. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
Farnie G; Sotgia F; Lisanti MP
Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting of lysosome and mitophagy in cancer stem cells with chloroquine analogues and antibiotics.
Al-Bari MAA
J Cell Mol Med; 2020 Oct; 24(20):11667-11679. PubMed ID: 32935427
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: the role of inhibition of Drp1 in ischemic brain damage.
Zuo W; Zhang S; Xia CY; Guo XF; He WB; Chen NH
Neuropharmacology; 2014 Nov; 86():103-15. PubMed ID: 25018043
[TBL] [Abstract][Full Text] [Related]
20. Mitophagy and age-related pathologies: Development of new therapeutics by targeting mitochondrial turnover.
Palikaras K; Daskalaki I; Markaki M; Tavernarakis N
Pharmacol Ther; 2017 Oct; 178():157-174. PubMed ID: 28461251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
